

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Line of Business: <input type="checkbox"/> Medicare	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

<p>Q1. Does the patient have the diagnosis of thrombocytopenia in a patient with chronic immune thrombocytopenia (ITP)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q2. Is the patient 1 year of age or older?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q3. Has the patient had an inadequate response, intolerance or contraindication to glucocorticoids (prednisone, high-dose dexamethasone, or high-dose methylprednisolone), immunoglobulins, or splenectomy?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q4. Des the patient have the diagnosis of thrombocytopenia in a patient with chronic hepatitis C?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q5. Is the patient 18 years of age or older?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q6. Has the patient's degree of thrombocytopenia prevented the initiation of interferon-based therapy or limited the ability to maintain interferon-based therapy?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q7. Does the patient have the diagnosis of severe aplastic anemia?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
<p>Q8. Is the patient 2 years of age or older?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q9. Has the patient had an inadequate response, intolerance or contraindication to immunosuppressive therapy, or will Promacta be used in combination with standard immunosuppressive therapy?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q10. Is Promacta being prescribed by or in consultation with a hematologist?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q11. Is Promacta being prescribed by or in consultation with a hematologist, hepatologist, or infectious disease specialist?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q12. Additional Information:</p>	
<p>Q13. Duration:</p> <p><input type="checkbox"/> 12 months <input type="checkbox"/> Other:</p>	

 Prescriber Signature

 Date

2022 Medicare Prior Authorization Request